Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab.
about
A Role for Notch Signalling in Breast Cancer and Endocrine ResistanceIdentifying and targeting tumor-initiating cells in the treatment of breast cancerCan nanomedicines kill cancer stem cells?Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitorsNANOMEDICINE: will it offer possibilities to overcome multiple drug resistance in cancer?Epidermal growth factor signaling in transformed cellsHER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancerSpontaneous epithelial-mesenchymal transition and resistance to HER-2-targeted therapies in HER-2-positive luminal breast cancer.Side-population cells in luminal-type breast cancer have tumour-initiating cell properties, and are regulated by HER2 expression and signallingPathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer.HER2 in Breast Cancer Stemness: A Negative Feedback Loop towards Trastuzumab Resistance.Top Notch cancer stem cells by paracrine NF-κB signaling in breast cancer.BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells.New promising drug targets in cancer- and metastasis-initiating cells.Suppression of apoptosis inhibitor c-FLIP selectively eliminates breast cancer stem cell activity in response to the anti-cancer agent, TRAIL.HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial.Targeting Notch signaling pathway to overcome drug resistance for cancer therapyBreast cancer stem cells: Multiple capacities in tumor metastasis.A Notch1-neuregulin1 autocrine signaling loop contributes to melanoma growth.Novel therapies against aggressive and recurrent epithelial cancers by molecular targeting tumor- and metastasis-initiating cells and their progenies.Determining duration of HER2-targeted therapy using stem cell extinction models.Proteomic comparison of mcf-7 tumoursphere and monolayer culturesCombined inhibition of ErbB1/2 and Notch receptors effectively targets breast ductal carcinoma in situ (DCIS) stem/progenitor cell activity regardless of ErbB2 status.Expression of stemness genes in primary breast cancer tissues: the role of SOX2 as a prognostic marker for detection of early recurrenceReduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenograftsRole of Notch and its oncogenic signaling crosstalk in breast cancer.New targeted therapies for breast cancer: A focus on tumor microenvironmental signals and chemoresistant breast cancersIn vitro analysis of breast cancer cell line tumourspheres and primary human breast epithelia mammospheres demonstrates inter- and intrasphere heterogeneity.The role of radiotherapy-resistant stem cells in breast cancer recurrence.An imbalance in progenitor cell populations reflects tumour progression in breast cancer primary culture models.Cancer stem cells and side population cells in breast cancer and metastasis.The emerging importance of α-L-fucose in human breast cancer: a review.Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence.HER2 and breast cancer stem cells: more than meets the eye.Modeling ductal carcinoma in situ: a HER2-Notch3 collaboration enables luminal filling.Breast cancer growth and metastasis: interplay between cancer stem cells, embryonic signaling pathways and epithelial-to-mesenchymal transition.NOTCH-1 and NOTCH-4 are novel gene targets of PEA3 in breast cancer: novel therapeutic implications.A positive cross-regulation of HER2 and ER-α36 controls ALDH1 positive breast cancer cellsMechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance.CD49f and CD61 identify Her2/neu-induced mammary tumor-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin-TGFβ signaling.
P2860
Q26765912-1BC662DE-E64E-402B-804A-CA668DAC0CA9Q26851827-CA00D852-F39F-43C9-9731-7304AE67A670Q27022017-F16A6D88-341B-438B-A12F-D8DB124B0F33Q27851975-7561EA35-A92F-4F22-9D23-7DBBACF500BAQ28078448-3B82EA90-98DD-4603-972E-7944FFA74C31Q28084034-6A304A2D-24F9-4389-92EB-839F8B942F41Q28476604-762B4368-6766-45FB-8932-59A5254E8193Q31132069-F0A3A272-7EA6-43A7-BFD4-7294ADAB5782Q33708119-26D3911F-3ACB-49FA-B74E-1A7E803B0761Q33737058-CE3DC4C9-20DC-4F0A-8A49-B69C5239794EQ33737278-015339E9-006D-43D6-8860-4CB6AB5D5930Q33745632-5829D799-AA9D-48EF-9DBB-CC116A1AD902Q33798713-20D69455-FEE0-40A6-9D99-DFB6F866324EQ34003691-4627BC9D-E846-4E4E-8079-E6BEDA215858Q34018500-D36BD8E6-4BC5-4ED2-BF05-8CD43890B9A2Q34194672-ED5AC2FC-A993-49DD-A729-D962530D743FQ34205088-39227C15-913A-4343-84CD-95DEC753A66CQ34257303-DE7A68DD-5A80-47B2-BF50-597D95A33E18Q34361366-A2965DBE-B7BE-421D-81E6-227EE00ABC84Q34382586-2A56A7B7-0219-42B0-9C8F-23C139364A98Q34531367-34A0C48C-87A7-46DD-A29A-7285E608EBFFQ34534423-070FA565-EC4C-4F66-BCB3-2BEE475674A0Q34607133-365631AC-0760-445D-AE2F-AC6FAAA44855Q34654576-061C41B0-EA80-4D1E-883C-B035F86435DEQ34694605-706FF725-44CC-4B4A-A726-97EA55B90527Q34697373-FC38F12C-9B72-4E0F-BBFC-CEE7FE361125Q34706060-DDFF62FD-1DF2-4239-81B0-8069DB58E651Q34764103-8A472F25-4783-4C6B-B877-1A9E9640875CQ34972167-24249865-3905-4297-8854-29A5B95BB3E1Q34980384-4FB643BB-811F-411F-A0D9-0A0B7E5FEF6CQ35038054-5035E4A4-0638-4E2F-9C02-08D12509086AQ35172546-810AA8A7-A4FE-4C3C-A73D-D9C37707120EQ35208201-0DB84093-5782-468F-9B9F-00EC4F81F322Q35320325-7131C2DD-CD24-4F64-9B77-95466083719FQ35354276-8A135D24-807D-4CC4-9014-C16E66210A73Q35558027-08EA9D1E-B2A7-424E-B799-1919A3E7898BQ35558109-118E4B44-E3A7-4920-B783-28215F170D1CQ35563328-06DF6910-A513-48E3-B285-C3F146679A39Q35624814-E78D35C5-41E1-491D-99ED-7A5770E6D833Q35678242-F0122B79-1D87-4B01-9080-B4B69D602E1E
P2860
Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Tumor-initiating cells of HER2 ...... are sensitive to trastuzumab.
@en
Tumor-initiating cells of HER2 ...... are sensitive to trastuzumab.
@nl
type
label
Tumor-initiating cells of HER2 ...... are sensitive to trastuzumab.
@en
Tumor-initiating cells of HER2 ...... are sensitive to trastuzumab.
@nl
prefLabel
Tumor-initiating cells of HER2 ...... are sensitive to trastuzumab.
@en
Tumor-initiating cells of HER2 ...... are sensitive to trastuzumab.
@nl
P2093
P50
P1476
Tumor-initiating cells of HER2 ...... are sensitive to trastuzumab.
@en
P2093
Alessandra Magnifico
Domenico Delia
Enrico Fontanella
Fabio Castiglioni
Luisa Albano
Sylvie Menard
P304
P356
10.1158/1078-0432.CCR-08-1327
P407
P577
2009-03-10T00:00:00Z